Akero therapeutics, inc. (AKRO)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-50,279

-43,755

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,792

1,770

0

0

0

Non-cash lease expense

0

-

-

-

-

Net amortization of premiums and discounts on short-term investments

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-20

507

0

0

0

Accounts payable

726

-426

0

0

0

Accrued expenses and other current liabilities

0

-

-

-

0

Net cash used in operating activities

-41,500

-35,627

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term marketable securities

0

-

-

-

-

Proceeds from maturities of short-term marketable securities

0

-

-

-

-

Net cash used in investing activities

0

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of stock options

0

-

-

-

-

Proceeds from the disgorgment of stockholders' short-swing profits, net

0

-

-

-

-

Payment of initial public offering costs

-

-

-

-

0

Net cash provided by (used in) financing activities

96,872

95,988

0

0

0

Net decrease in cash, cash equivalents and restricted cash

-22,422

-11,152

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Net unrealizable gain on marketable securities

0

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses and other current liabilities

-

-

-

0

0